Serotonergic vulnerability and depression: assumptions, experimental evidence and implications

In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotone...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular psychiatry 2007-06, Vol.12 (6), p.522-543
Hauptverfasser: Jans, L A W, Riedel, W J, Markus, C R, Blokland, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 543
container_issue 6
container_start_page 522
container_title Molecular psychiatry
container_volume 12
creator Jans, L A W
Riedel, W J
Markus, C R
Blokland, A
description In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.
doi_str_mv 10.1038/sj.mp.4001920
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70538767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188547030</galeid><sourcerecordid>A188547030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</originalsourceid><addsrcrecordid>eNqFktuL1TAQh4so7kUffVSKiz7ZY9LcfVsWb7Dgg_pqSNPpIYc2rUm7uP-9s3uqB8VFAsmQ-X5zSaYonlCyoYTp13m3GaYNJ4SamtwrjilXshJC6ftoM2EqTjU_Kk5y3iGDTvGwOKKKSkKkOi6-fYY0zmOEtA2-vFp6tFwT-jBfly62ZQtTgpzDGN-ULudlmGa086sSfkyQwgBxdn0JV6GF6OFWEoapD97dco-KB53rMzxez9Pi67u3Xy4-VJef3n-8OL-svNR8rnRDjWl05ziTrmmUIL4xrZDAfKuNVzX3hFPFNWWUSKEEk5q0XNcNow1nwE6Ll_u4Uxq_L5BnO4Tsoe9dhHHJVhHBtJLqvyA1UktuNIJnf4G7cUkRm7C15EJJ3CVSz--kakplbbg5hNq6HmyI3Tgn52_y2nOqteCKMILU5h8UrhaG4PGHuoD3fwiqvcCnMecEnZ3wQ1y6tpTYm9mweWeHya6zgfyztdalGaA90OswIPBiBVz2ru-Siz7kA4cPiPMjD5VmdMUtpEPTd2V-uhdENy8Jfkf85f8JN_HYww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221162949</pqid></control><display><type>article</type><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</creator><creatorcontrib>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</creatorcontrib><description>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/sj.mp.4001920</identifier><identifier>PMID: 17160067</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult and adolescent clinical studies ; Animals ; Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Depression ; Depression - metabolism ; Depressive Disorder - metabolism ; Drugs ; Emotional disorders ; Environment ; feature-review ; Female ; Genetic factors ; Humans ; Hypotheses ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Mental depression ; Metabolism ; Metabolites ; Models, Neurological ; Mood disorders ; Neurosciences ; Pathology ; Pharmacotherapy ; Psychiatry ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Serotonin ; Serotonin - deficiency ; Serotonin - metabolism ; Sex Factors ; Tryptophan</subject><ispartof>Molecular psychiatry, 2007-06, Vol.12 (6), p.522-543</ispartof><rights>Springer Nature Limited 2007</rights><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2007</rights><rights>Nature Publishing Group 2007.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</citedby><cites>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.mp.4001920$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.mp.4001920$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18764766$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17160067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jans, L A W</creatorcontrib><creatorcontrib>Riedel, W J</creatorcontrib><creatorcontrib>Markus, C R</creatorcontrib><creatorcontrib>Blokland, A</creatorcontrib><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</description><subject>Adult and adolescent clinical studies</subject><subject>Animals</subject><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Depression</subject><subject>Depression - metabolism</subject><subject>Depressive Disorder - metabolism</subject><subject>Drugs</subject><subject>Emotional disorders</subject><subject>Environment</subject><subject>feature-review</subject><subject>Female</subject><subject>Genetic factors</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental depression</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Models, Neurological</subject><subject>Mood disorders</subject><subject>Neurosciences</subject><subject>Pathology</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Serotonin</subject><subject>Serotonin - deficiency</subject><subject>Serotonin - metabolism</subject><subject>Sex Factors</subject><subject>Tryptophan</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFktuL1TAQh4so7kUffVSKiz7ZY9LcfVsWb7Dgg_pqSNPpIYc2rUm7uP-9s3uqB8VFAsmQ-X5zSaYonlCyoYTp13m3GaYNJ4SamtwrjilXshJC6ftoM2EqTjU_Kk5y3iGDTvGwOKKKSkKkOi6-fYY0zmOEtA2-vFp6tFwT-jBfly62ZQtTgpzDGN-ULudlmGa086sSfkyQwgBxdn0JV6GF6OFWEoapD97dco-KB53rMzxez9Pi67u3Xy4-VJef3n-8OL-svNR8rnRDjWl05ziTrmmUIL4xrZDAfKuNVzX3hFPFNWWUSKEEk5q0XNcNow1nwE6Ll_u4Uxq_L5BnO4Tsoe9dhHHJVhHBtJLqvyA1UktuNIJnf4G7cUkRm7C15EJJ3CVSz--kakplbbg5hNq6HmyI3Tgn52_y2nOqteCKMILU5h8UrhaG4PGHuoD3fwiqvcCnMecEnZ3wQ1y6tpTYm9mweWeHya6zgfyztdalGaA90OswIPBiBVz2ru-Siz7kA4cPiPMjD5VmdMUtpEPTd2V-uhdENy8Jfkf85f8JN_HYww</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Jans, L A W</creator><creator>Riedel, W J</creator><creator>Markus, C R</creator><creator>Blokland, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><author>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Animals</topic><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Depression</topic><topic>Depression - metabolism</topic><topic>Depressive Disorder - metabolism</topic><topic>Drugs</topic><topic>Emotional disorders</topic><topic>Environment</topic><topic>feature-review</topic><topic>Female</topic><topic>Genetic factors</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental depression</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Models, Neurological</topic><topic>Mood disorders</topic><topic>Neurosciences</topic><topic>Pathology</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Serotonin</topic><topic>Serotonin - deficiency</topic><topic>Serotonin - metabolism</topic><topic>Sex Factors</topic><topic>Tryptophan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jans, L A W</creatorcontrib><creatorcontrib>Riedel, W J</creatorcontrib><creatorcontrib>Markus, C R</creatorcontrib><creatorcontrib>Blokland, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jans, L A W</au><au>Riedel, W J</au><au>Markus, C R</au><au>Blokland, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>12</volume><issue>6</issue><spage>522</spage><epage>543</epage><pages>522-543</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>17160067</pmid><doi>10.1038/sj.mp.4001920</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-4184
ispartof Molecular psychiatry, 2007-06, Vol.12 (6), p.522-543
issn 1359-4184
1476-5578
language eng
recordid cdi_proquest_miscellaneous_70538767
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adult and adolescent clinical studies
Animals
Behavioral Sciences
Biological and medical sciences
Biological Psychology
Depression
Depression - metabolism
Depressive Disorder - metabolism
Drugs
Emotional disorders
Environment
feature-review
Female
Genetic factors
Humans
Hypotheses
Male
Medical sciences
Medicine
Medicine & Public Health
Mental depression
Metabolism
Metabolites
Models, Neurological
Mood disorders
Neurosciences
Pathology
Pharmacotherapy
Psychiatry
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Serotonin
Serotonin - deficiency
Serotonin - metabolism
Sex Factors
Tryptophan
title Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A15%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serotonergic%20vulnerability%20and%20depression:%20assumptions,%20experimental%20evidence%20and%20implications&rft.jtitle=Molecular%20psychiatry&rft.au=Jans,%20L%20A%20W&rft.date=2007-06-01&rft.volume=12&rft.issue=6&rft.spage=522&rft.epage=543&rft.pages=522-543&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/sj.mp.4001920&rft_dat=%3Cgale_proqu%3EA188547030%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221162949&rft_id=info:pmid/17160067&rft_galeid=A188547030&rfr_iscdi=true